Prevalence and Clinical Conditions Related to Sarcopaenia among Older Persons Living in the Community

Encarnación Blanco-Reina 1,*, Ricardo Ocaña-Riola 2, Gabriel Ariza-Zafra 3, María Rosa García-Merino 4, Lorena Aguilar-Cano 5, Jenifer Valdellós 4, Claudia Torres-Blanco 6 and Inmaculada Bellido-Estévez 1

1 Pharmacology and Therapeutics Department, Instituto de Investigación Biomédica de Málaga-IBIMA, School of Medicine, University of Málaga, 29016 Málaga, Spain; ibellido@uma.es
2 Escuela Andaluza de Salud Pública, 18011 Granada, Spain; ricardo.ocana.easp@juntadeandalucia.es
3 Geriatrics Department, Complejo Hospitalario Universitario, 02006 Albacete, Spain; gariza@sescam.jccm.es
4 Health District of Málaga-Guadalhorce, 29009 Málaga, Spain; rosaballet@yahoo.es (M.R.G.-M.); jenny_dok7@hotmail.com (J.V.)
5 Physical Medicine and Rehabilitation Department, Hospital Regional Universitario, 29010 Málaga, Spain; loagca2011@hotmail.com
6 Pharmacology and Therapeutics Department, School of Medicine, University of Málaga, 29016 Málaga, Spain; claudiatblanco4@gmail.com

* Correspondence: eblanco@uma.es; Tel.: +34-952-136-648

Abstract: (1) Background: In health care and in society at large, sarcopaenia is a disorder of major importance that can lead to disability and other negative health-related events. Our study aim is to determine the prevalence of sarcopaenia among older people attended in primary care and to analyse the factors associated with this age-related clinical condition; (2) Methods: A multicentre cross-sectional study was conducted of 333 community-dwelling Spanish adults aged 65 years or more. Sociodemographic, clinical, functional, anthropometric, and pharmacological data were collected. Sarcopaenia was defined following European Working Group on Sarcopaenia in Older People (EWGSOP) criteria; (3) Results: Sarcopaenia was present in 20.4% of the study sample, and to a severe degree in 6%. The intensity of the association between sarcopaenia and frailty was weak-moderate (Cramer V = 0.45). According to the multinomial logistic regression model performed, sarcopaenia was positively associated with age and with the presence of psychopathology (OR = 2.72; 95% CI = 1.30–5.70) and was inversely correlated with body mass index (OR = 0.73, 95% CI = 0.67–0.80); (4) Conclusions: Sarcopaenia commonly affects community-dwelling older persons and may be associated with age, body mass index, and psychopathology. The latter factor may be modifiable or treatable and is therefore a possible target for intervention.

Keywords: sarcopaenia; older adults; primary care; psychopathology; frailty; body mass index

1. Introduction

In recent years, there has been growing interest in identifying age-related conditions that can lead to disability. In this context, special attention has been paid to the study of sarcopaenia, a condition that is closely related to physical function impairment. The term sarcopaenia was originally proposed in 1989 to describe age-related decrease in muscle mass [1,2]. Subsequently, various operational definitions and diagnostic criteria have been proposed. It has been suggested that defining sarcopaenia only in terms of muscle mass is of very limited value, for several reasons. Firstly, the association between this criterion alone and adverse health outcomes is weak. Moreover, muscle strength does not depend exclusively on muscle mass, and the relationship between them is not linear [3,4]. In response to these observations, a functional dimension has been added to the term. In 2010, the European Working Group on Sarcopaenia in Older People (EWGSOP) provided a working definition for sarcopaenia [5], proposing that it be diagnosed using...
the twin criteria of low muscle mass and low muscle function (either low strength and/or low physical performance). This operational definition represented an important change and is currently in wide use, worldwide. More recently, however, in order to reflect the growing body of new scientific and clinical evidence regarding this question, the EWGSOP recommendations have been updated (as EWGSOP2) [6], and the broad description of sarcopaenia is that it is a muscle disease (or failure) rooted in adverse muscle changes that accrue over a lifetime. In fact, sarcopaenia is already formally recognised as a muscle disease, with a specific ICD-10-MC diagnosis code, which represents an important step forward towards a generally accepted classification [7,8].

Progressive muscle loss in the elderly is due in part to physiological age-related changes, such as the loss of motoneuron units, decreased hormone status, and increased insulin sensitivity, which in turn lead to increased proteolysis, decreased muscle protein synthesis, and increased fat infiltration of the muscle [9]. Other factors that may contribute to the development of sarcopaenia include immobility, inflammation, an inactive lifestyle, and malnutrition. We believe it important to seek a better understanding of this geriatric syndrome due to its prevalence, its association with negative health-related events, the existence of certain potentially reversible factors, and because it is, at least initially, a treatable condition. In this respect, physical exercise to gain muscle resistance and a focused nutritional intervention are of fundamental importance.

Widely varying accounts have been given of the prevalence of sarcopaenia [10–14]. In part, this is because it depends on the characteristics of the population under study (such as age, gender, comorbidity, and race) and on the healthcare setting considered, but the value obtained is also subject to the methodology used to assess muscle mass and even to the definition made of sarcopaenia [11]. Even when focusing exclusively on community-dwelling older people, the heterogeneity of the samples analysed, the criteria used, and the cut-off points selected combine to affect the prevalence obtained, reported values of which range from 6% to 59.8% [11], or from 9.9% to 40.4% according to other sources [12–14]. In any case, the global rate of sarcopaenia is undoubtedly rising across the world, and the impact is especially high among the elderly population in nursing homes and those who are hospitalised or in rehabilitation units [11].

Sarcopaenia has a major impact on society and its healthcare systems, imposing severe personal, social, and economic burdens [15]. Among other consequences, it increases the risk of falls and fractures [16,17], impairs patients’ ability to perform activities of daily living [18], provokes mobility disorders [19], limits independence [20], decreases the quality of life [21], and can even lead to death [22,23].

In view of these considerations, a heightened awareness of the dangers of sarcopaenia should become a part of clinical routine, with special regard to community-dwelling older persons. Primary care is the most common health contact point for most of the older population. Moreover, attention is usually comprehensive and personalised, making this healthcare environment very suitable for the identification, management, and study of sarcopaenia. However, the assessment and treatment of sarcopaenia at the outpatient level is still uncommon. Accordingly, this complex syndrome is probably underdiagnosed [24]. In view of its relationship with disability and other negative health-related events, and the need to continue characterising its prevalence in different settings, the present study was designed to address these questions. The progression of sarcopaenia depends on various factors, and their joint effects are directly relevant to the possibilities of prevention and treatment [25]. The main aim of the present study is to determine the prevalence of sarcopaenia among older adults living in the community in Spain, where life expectancy rates are among the highest in the world [26], and to analyse related factors, some of which are potentially modifiable through specific interventions and preventive actions.

2. Materials and Methods

This multicentre cross-sectional study was carried out within a primary healthcare context.
2.1. Reference Population and Study Sample

The study sample was composed of persons aged 65 years or more, living in the community, attended at primary care centres in Malaga (Spain). All participants were registered in the database of the Spanish NHS, were treated in an outpatient setting (i.e., not institutionalised), and provided signed informed consent to take part in the study. As exclusion criteria, none had implanted metal devices (pacemakers or osteoarticular prostheses, because they might cause interference with electric bioimpedanciometry measurements), had suffered the complete or partial amputation of a limb, or had an advanced or terminal illness. The patients were recruited at nine primary healthcare centres, using stratified random sampling designed to obtain a representative sample. The study population was allocated in proportion to the size of each healthcare centre. Based on a published prevalence of sarcopaenia in primary care of 22% [27,28] and assuming a margin of error of less than 4.5% and a 95% confidence interval, we calculated that the minimum sample size required for this study would be 325 persons.

2.2. Data Collection and Global Assessment

The participants were interviewed using a structured questionnaire, and various physical tests were conducted to assess the presence and degree of sarcopaenia. Further data were obtained from medication packaging and digital medical records. A complete set of sociodemographic, clinical, functional, and pharmacological data were collected from all participants. The clinical data included all diseases recorded, possible comorbidities, and Charlson’s comorbidity index (CCI) [29]. Information was also obtained about the medication prescribed (indication, dosage, and duration of any treatment received during the last three months or more). Polypharmacy was defined as the chronic prescription of five or more drugs.

Cognitive function was evaluated using Pfeiffer’s short portable mental state questionnaire (SPMSQ) [30], and mood status was determined using Yesavage’s geriatric depression scale (GDS-15) [31]. The patients’ independence in performing instrumental activities of daily living (IADL) was assessed using the Lawton scale [32]. The body mass index (BMI) was calculated, and nutritional screening was performed using the Spanish version (Nestlé Nutrition Institute) of the Mini Nutritional Assessment-Short Form [33]. The different BMI categories (underweight, normal, overweight, and obesity) were operationalised following the World Health Organization cut-off values.

Frailty was assessed according to the phenotype proposed by Fried et al. [34], which consists of the following criteria: (a) unintentional weight loss of 4.5 kg or more in the previous year; (b) self-reported exhaustion, identified by two questions on the Center for Epidemiological Studies Depression (CES-D) scale; (c) weakness, defined by low handgrip strength and measured in kg in the dominant hand using a dynamometer (highest of three consecutive measurements), adjusted for gender and BMI (grip strength was classified as low when the force exerted was below the first quintile of the distribution); (d) slow walking speed (lowest quintile of gait speed), assessed by the walking time (in seconds) over a distance of 4.57 m, adjusted for gender and height; and (e) low physical activity, measured by the weighted score of kilocalories expended per week, obtained from the Minnesota Leisure Time Activity Questionnaire and adjusted for gender. Participants were classified as non-frail (robust) if they met none of the criteria, pre-frail if they met one or two criteria, and frail if three or more criteria were met.

2.3. Assessment of Sarcopaenia

The main study outcome was sarcopaenia, which was defined following EWGSOP criteria [5]. According to these criteria, diagnosis of sarcopaenia required the documentation of low muscle mass plus the documentation of either low muscle strength or low physical performance.
2.3.1. Muscle Mass

Muscle mass was measured by bioelectrical impedance analysis (BIA). The BIA resistance (measurement range 150–1200 Ohms) was determined using a Tanita BC-418 body composition analyser (Tanita Corporation, Tokyo, Japan) with an 8-electrode method and an operating frequency of 50 kHz. Muscle mass was calculated using Janssen’s bioelectrical impedance analysis equation [35]. Absolute skeletal muscle mass was converted to skeletal muscle index (SMI) by dividing the limb skeletal muscle mass (kg) by the square of the height (m²). Low muscle mass was defined as the SMI of two standard deviations (SDs) or more below the normal sex-specific mean for young persons. Using the cut-off points indicated in the EWGSOP consensus, low muscle mass was classified as SMI < 8.87 kg/m² in men and < 6.42 kg/m² in women.

2.3.2. Muscle Strength

Muscle strength was assessed by grip strength, measured using a Jamar hydraulic grip hand dynamometer SP-5030J1 (Lafayette Instrument Company, Lafayette, IN, USA). Patients were instructed to perform a maximal isometric contraction, and the highest value of three consecutive measurements was recorded. BMI-adjusted values were used as cut-off points to classify low muscle strength (following EWGSOP recommendations for men/women) [5].

2.3.3. Physical Performance

Usual walking speed (m/s) on a 4-metre course was used as an objective measure of physical performance. The time elapsed from the start to the finish point was recorded by an investigator with a digital chronometer, and the best time of two attempts was recorded. A cut-off point of 0.8 m/s or less in gait speed was used to define low physical performance [5].

Sarcopaenia was diagnosed as follows: low muscle mass alone was defined as pre-sarcopaenia; the joint presence of low muscle mass and low muscle strength or low performance was defined as sarcopaenia; and the presence of all three criteria was considered as severe sarcopaenia.

All data were measured and collected by primary care clinicians, who were active members of the research team.

2.4. Statistical Analysis

Exploratory data analysis and frequency tables were used to describe the study variables. Taking into account the four possible categories of the main variable according to the EWGSOP conceptual stages of sarcopaenia (pre-sarcopaenia, sarcopaenia, severe sarcopaenia, and no sarcopaenia), a multinomial logistic regression model was used to study the relationship between the independent variables and the outcome variable, sarcopaenia [36]. All independent variables were included in the regression model. The influence of various factors on the states of pre-sarcopaenia, sarcopaenia, and severe sarcopaenia was examined, taking non-sarcopaenic patients as a benchmark. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for each covariate included in the model. A 5% significance level was assumed to indicate statistical significance. All statistical data analyses were performed using SPSS version 24.0 (IBM SPSS Statistics, Armonk, NY, USA).

2.5. Ethical Considerations

This study was conducted in accordance with the Declaration of Helsinki. The Málaga Clinical Research Ethics Committee approved the study (PI-0234-14), and informed consent was obtained from all patients prior to their inclusion.
3. Results
3.1. Characteristics of the Study Population

The study population consisted of 333 community-dwelling Spanish adults aged 65 years or more. Their mean age was 72.81 years (standard deviation 5.1, range 65–91), and slightly more than half were female. Only 19.5% lived alone; the rest lived with a partner, family member(s), or caretaker (professional or otherwise). The average CCI score was 1.30 (standard deviation 1.4, range 0–7), and 33.3% of the patients had a score > 2. Each patient presented an average of 7.4 diagnoses (standard deviation 3.4, range 0–20) and was consuming 6.5 drugs (standard deviation 4.0; range 0–21), with a polymedication prevalence of 65.8%. The most prevalent chronic conditions were bone and joint disorders (mainly osteoarthritis of the knee, hip, hand, and shoulder) (76.9%), hypertension (68.2%), and dyslipidaemia (51.7%). Some form of psychopathology (mainly anxiety and/or depression) was present in 37.8% of the patients, and 42.6% suffered insomnia. The mean score on the Lawton scale was 6.7 (standard deviation 1.7, range 0–8) with half of the sample being independently capable of performing IADL. Regarding anthropometric and nutritional characteristics, the mean BMI was 30.3 kg/m$^2$ (standard deviation 4.9, range 18.9–52.3). Only 14.7% of the patients had a normal weight; 39.6% presented overweight and 45.6% obesity. Among the participants with obesity, more than half (56.6%) were class I (30–34.9 kg/m$^2$), 34.9% were class II (35–39.9 kg/m$^2$), and 8.5% were obesity class III or severe (>40 kg/m$^2$). Nevertheless, according to the MNA, 95.5% of the participants had a good nutritional status and only 3.3% were at risk of malnutrition or were malnourished (1.2%). The sociodemographic, functional, cognitive, and clinical characteristics of the study participants are summarised in Table 1.

Table 1. Characteristics of the study population ($n = 333$).

| Quantitative Variables | Mean   | Standard Deviation |
|------------------------|--------|--------------------|
| Age (years)            | 72.8   | 5.1                |
| Lawton (IADL)          | 6.7    | 1.7                |
| BMI (kg/m$^2$)         | 30.3   | 4.9                |
| Number of comorbidities| 7.4    | 3.4                |
| Number of drugs per patient | 6.5 | 4                  |

| Qualitative Variables  | Subjects ($n$) | Percentage (%) |
|------------------------|----------------|----------------|
| Gender                 |                |                |
| Male                   | 138            | 41.4           |
| Female                 | 195            | 58.6           |
| Lawton (IADL)          |                |                |
| 0–1                    | 4              | 1.2            |
| 2–3                    | 19             | 5.7            |
| 4–5                    | 44             | 13.2           |
| 6–7                    | 95             | 28.5           |
| 8                      | 171            | 51.4           |
| SPMSQ (Pfeiffer)       |                |                |
| 0–2 errors             | 305            | 91.6           |
| 3–4 errors             | 21             | 6.3            |
| 5 errors and over      | 7              | 2.1            |
| GDS-15                 |                |                |
| 0–5                    | 255            | 76.6           |
| 6–9                    | 56             | 16.8           |
| 10 and over            | 22             | 6.6            |
| BMI categories         |                |                |
| Underweight            | 0              | 0              |
Table 1. Cont.

| Qualitative Variables                      | Subjects (n) | Percentage (%) |
|--------------------------------------------|--------------|----------------|
| Normal                                     | 49           | 14.7           |
| Overweight                                 | 132          | 39.6           |
| Obese                                      | 152          | 45.6           |
| Nutritional status                         |              |                |
| Normal                                     | 318          | 95.5           |
| Malnutrition risk                          | 11           | 3.3            |
| Malnourished                               | 4            | 1.2            |
| Charlson Comorbidity Index                 |              |                |
| 0–1                                        | 219          | 65.8           |
| 2                                          | 53           | 15.9           |
| 3 or more                                  | 61           | 18.3           |
| Specific comorbidities                     |              |                |
| Bone and joint disorders                   | 256          | 76.9           |
| Hypertension                               | 227          | 68.2           |
| Dyslipidaemia                              | 172          | 51.7           |
| Insomnia                                   | 142          | 42.6           |
| Psychopathology                            | 126          | 37.8           |
| Diabetes mellitus                          | 89           | 26.8           |
| Heart disease                              | 81           | 24.3           |
| Respiratory disease                        | 125          | 21.5           |
| Osteoporosis                               | 57           | 17.1           |
| Polymedication                             | 219          | 65.8           |
| Frailty states                             |              |                |
| Robust (non-frail)                         | 72           | 21.6           |
| Pre-frail                                  | 190          | 57.1           |
| Frail                                      | 71           | 21.3           |
| Fried criterion                            |              |                |
| Unintentional weight loss                  | 22           | 6.6            |
| Exhaustion                                 | 68           | 20.4           |
| Weakness                                   | 209          | 62.8           |
| Slow walking speed                         | 59           | 17.7           |
| Low physical activity                      | 164          | 49.2           |

IADL: Instrumental activities of daily living; BMI: Body mass index (0.0–18.5: underweight; 18.5–24.9: normal; 25.0–29.9: overweight; 30 and over: obese); SPMSQ: Short Portable Mental Status Questionnaire (0–2 errors: normal mental functioning; 3–4 errors: mild cognitive impairment; 5 errors and over: moderate-severe cognitive impairment); GDS-15: Geriatric Depression Scale (0–5: no depression; 6–9: suggestive of depression; 10 and over: almost always depression).

Frailty was present in 21.3% of participants; 57.1% were pre-frail and 21.6% were non-frail. The most prevalent Fried phenotype criterion observed in the sample was weakness (62.8%), followed by low physical activity (49.2%) and exhaustion (20.4%).

3.2. Assessment of Sarcopenia and Related Factors

According to the EWGSOP algorithm, 20.4% of the community-dwelling older adults in the sample had sarcopenia, and 6% had severe sarcopenia. Slightly more than half (57.7%) of the participants did not meet any criteria for sarcopenia and 15.9% were considered pre-sarcopenic (low muscle mass alone) (Table 2). The mean SMI was 7.6 kg/m² (standard deviation 1.4; range 4.8–12.0). For the female participants, the mean SMI was 6.7 kg/m² (standard deviation 0.8; range 4.8–9.2), and for the men, it was 9.0 kg/m² (standard deviation 0.9; range 5.8–12.0). Therefore, sarcopenia was present, overall, in 26.4% of this elderly population. The condition was more common in women (29.2%) than in men (22.5%), and among the non-obese than the obese (37% vs. 13.8%, respectively; p < 0.001). The coincidence of obesity and sarcopenia was present in 6.3% of the sample. In this respect, too, the mean BMI was higher in non-sarcopenic than in sarcopenic patients (31.3 kg/m² versus 27.6 kg/m², respectively; p < 0.001).
Table 2. Sarcopenia categories and criteria according to EWGSOP ($n = 333$).

| Sarcopenia categories       | Subjects ($n$) | Percentage (%) |
|-----------------------------|----------------|----------------|
| No sarcopenia               | 192            | 57.7           |
| Pre-sarcopenia              | 53             | 15.9           |
| Sarcopenia                  | 68             | 20.4           |
| Severe sarcopenia           | 20             | 6              |

| Criteria                     | Subjects ($n$) | Percentage (%) |
|------------------------------|----------------|----------------|
| Low muscle mass              | 141            | 42.3           |
| Low muscle strength          | 209            | 62.8           |
| Slow walking speed           | 59             | 17.7           |

Categories: No sarcopenia: 0 criteria present; Pre-sarcopenia: low muscle mass alone; Sarcopenia (2 criteria present): low muscle mass + low muscle strength or low performance; Severe sarcopenia: 3 criteria present.

Regarding the combination of sarcopenia and frailty, 7.8% of participants were both frail and sarcopenic, while 13.5% were frail-only. None were sarcopenic-only. Therefore, there were no patients who were sarcopenic and robust at the same time, and all sarcopenic individuals were either in a state of pre-frailty (70.5%) or one of frailty (29.5%). The prevalence of frailty among those with sarcopenia was 40.2%; among those with frailty, the prevalence of sarcopenia was 36.6%. The intensity of the association between sarcopenia and frailty was weak-moderate (Cramer $V = 0.45$).

A multinomial logistic regression analysis was performed to further examine the influence of the independent variables on the EWGSOP sarcopenia categories (Table 3). The two factors that were most consistently associated with the presence of sarcopenia were BMI and the diagnosis of a psychopathology. In fact, the odds of presenting sarcopenia and severe sarcopenia decreased by 27% and 25% for each additional point ($\text{kg/m}^2$) of BMI (OR = 0.73, 95% CI = 0.67–0.80; OR = 0.75, 95% CI = 0.66–0.86), respectively. However, these odds rose sharply for persons with a psychopathology, for all states of sarcopenia. Thus, the OR of patients with vs. without a psychopathology were 2.56 (95% CI = 1.06–6.19) for pre-sarcopenia, 2.72 (95% CI = 1.30–5.70) for sarcopenia, and 7.89 (95% CI = 2.25–27.59) for severe sarcopenia, with all other covariates being equal. No relevant association was found between sarcopenia and the other prevalent pathologies considered or with the number of medications consumed. In this population sample, gender did not behave as a predictor variable; however, age was related to severe sarcopenia. Thus, for each additional year of life, the odds of presenting severe sarcopenia increased by 10% (OR = 1.11, 95% CI = 1.01–1.22).

Table 3. Factors related to sarcopenia. Multinomial logistic regression for pre-sarcopenia, sarcopenia, and severe sarcopenia states (with respect to non-sarcopenic).

| Independent Variable | Pre-Sarcopenia OR (95% CI) | Sarcopenia OR (95% CI) | Severe Sarcopenia OR (95% CI) |
|----------------------|-----------------------------|------------------------|-------------------------------|
| Age                  | 0.94 (0.87–1.02) *           | 0.98 (0.92–1.04)       | 1.11 (1.01–1.22) *            |
| Number of comorbidities | 0.79 (0.65–0.97) *          | 0.92 (0.78–1.08)       | 1.04 (0.82–1.33)              |
| Number of medicines  | 1.08 (0.95–1.24)            | 0.98 (0.87–1.10)       | 1.03 (0.85–1.24)              |
| BMI                  | 0.74 (0.67–0.83) ***         | 0.73 (0.67–0.80) ***   | 0.75 (0.66–0.86) ***           |
| Gender               |                             |                        |                              |
| Male                 | 0.51 (0.22–1.18)            | 0.64 (0.31–1.31)       | 0.46 (0.11–1.84)              |
| Female               |                              | 1                      | 1                             |
| Diabetes mellitus    |                             |                        |                              |
| Yes                  | 1.12 (0.45–2.76)            | 0.76 (0.33–1.74)       | 2.58 (0.79–8.41)              |
| No                   |                              | 1                      | 1                             |
Table 3. Cont.

| Independent Variable          | Pre-Sarcopaenia OR (95% CI) | Sarcopaenia OR (95% CI) | Severe Sarcopaenia OR (95% CI) |
|-------------------------------|-----------------------------|-------------------------|-------------------------------|
| Heart disease                 |                             |                         |                               |
| Yes                           | 1.04 (0.34–3.09)            | 1.09 (0.43–2.75)        | 0.44 (0.89–2.24)              |
| No                            | 1                           | 1                       | 1                             |
| Bone and joint disorder       |                             |                         |                               |
| Yes                           | 0.38 (0.16–0.89) *          | 0.73 (0.32–1.65)        | 1.59 (0.16–15.09)             |
| No                            | 1                           | 1                       | 1                             |
| Osteoporosis                  |                             |                         |                               |
| Yes                           | 0.87 (0.31–2.45)            | 0.28 (0.10–0.79) *      | 1.10 (0.34–3.58)              |
| No                            | 1                           | 1                       | 1                             |
| Psychopathology               |                             |                         |                               |
| Yes                           | 2.56 (1.06–6.19) *          | 2.72 (1.30–5.70) **     | 7.89 (2.25–27.59) ***         |
| No                            | 1                           | 1                       | 1                             |
| Low physical activity         |                             |                         |                               |
| Yes                           | 0.31 (0.13–0.72) *          | 0.95 (0.48–1.85)        | 1.90 (0.59–6.09)              |
| No                            | 1                           | 1                       | 1                             |

OR: odds ratio; BMI: Body mass index (kg/m²). * p < 0.05; ** p < 0.01; *** p < 0.001.

4. Discussion

The results of the present study show that sarcopenia (assessed using the EWGSOP algorithm) is present in about a quarter of community-dwelling older patients (sarcopenia in 20.4% and severe sarcopenia in 6%). These prevalence data are slightly higher than those reported by similar studies conducted in Spain [27] or elsewhere [28] and are close to the upper limit of the expected range in this health setting. Systematic reviews of studies also carried out on elderly outpatient populations, using the same diagnostic criteria, have reported prevalences ranging from 9.9–40.4% [13], 1–33 % [10], and 10–27% [37]. This considerable heterogeneity between the studies may reflect differences in the diagnostic criteria used, in the cut-off points chosen, and in the characteristics of the target population. In our study, the EWGSOP algorithm was used because it was the working definition most commonly employed when the study began, and thus provided the best comparability with previous work in this area. Moreover, the EWGSOP operational definition offered cut-off points for muscle strength that corresponded to those of the weakness item in the Fried criteria. Very recent studies have shown that the EWGSOP2 diagnostic criteria detect lower prevalences than EWGSOP [38], i.e., the 2010 original version presents greater sensitivity [39].

According to our findings, sarcopenia is positively associated with age and with the presence of one or more psychopathologies, and inversely correlated with BMI. In our study population, the prevalence of sarcopenia was higher in women than in men, but a statistically significant association with gender was not confirmed in the multivariate regression model. Although some studies have observed a higher prevalence in the female population [40], most systematic reviews report that more men than women are affected by sarcopenia [11,14]. There is no clear explanation in this regard, nor has this conclusion been definitively established. It has been suggested that the cut-off value threshold could influence the question [41], or that reduced functional status in men is more closely related to the loss of muscle mass, while in women this decline would be more associated with osteoarthritis, osteoporosis, or depression [42]. We did find a significant relationship with age, such that for each additional year of life, the odds of presenting severe sarcopenia increased by 10%. This is a biologically plausible result that is consistent with previous findings [40,43,44].

Regarding comorbidities, the clinical condition that was associated with all states of sarcopenia was the diagnosis of psychopathology (mainly anxiety and depression), which doubled the odds of a patient presenting pre-sarcopenia or sarcopenia and multiplied
them by seven for severe sarcopaenia. Sarcopaenia has most frequently been associated with other chronic conditions such as chronic lung disease, neurological disease, and neoplasia. However, some evidence of a relationship with depression has also been observed, but this association appears to be weaker and is less commonly reported [45–47]. An association has also been reported between mental pathology and frailty [48,49]. It has been observed that persons with a psychopathology tend to be less physically active, to have a less active social life, and to consume a less healthy diet, and that any or all of these factors could be related to a loss of strength and muscle mass.

Our findings show that after adjusting for potential confounders, BMI is closely associated with sarcopaenia. Thus, the odds of a patient presenting sarcopaenia and severe sarcopaenia decrease by 27% and 25% for each additional point (kg/m$^2$) of BMI, respectively. In consequence, we found the prevalence of sarcopaenia among those with obesity to be significantly lower than among the non-obese population (13.8% vs. 37%, respectively). This inverse relationship between BMI and sarcopaenia is consistent with other studies [43,44]. However, although BMI has been considered an approximate marker of nutritional status, sarcopaenia sometimes coexists with obesity. In our study sample, the prevalence of sarcopaenic obesity was 6.3%, an intermediate figure according to data from a recent systematic review and meta-analysis (2–9%) [37]. It seems that adipose inflammation leads to intra-abdominal fat redistribution and fat infiltration in the muscle. Accordingly, synergy between the loss of muscle mass and this fat infiltration could trigger the pathogenesis of sarcopaenic obesity [50]. In any case, the nutritional status of our community-dwelling older persons was very good (only 1.2% malnutrition), but the presence of obesity was high compared to previous reports. Thus, a study of older adults in 21 European countries reported only 20.9% obesity compared to 45.6% in our sample population [51]. Among other causes, this high prevalence could be due to a certain north-south gradient. According to a national study conducted in Spain, obesity is higher in the south (where Malaga is located) than in the rest of the country [52].

The coexistence of frailty and sarcopaenia was observed in 7.8% of the patients in our study. This rate is lower than that found in another multicentre study conducted in Spain, but the latter focused on hospitalised patients with a higher disease burden, which would explain the discrepancy (18%) [43]. In a recent cohort study of community-dwelling older adults in Australia, more similar to ours, only 2.8% of participants were both frail and sarcopaenic. Among these participants, with either condition, the risk of mortality was over three times higher [53]. The prevalence of frailty among those with sarcopaenia was 40.2%, and that of sarcopaenia among frail patients was 36.6%, results very similar to those found by Reijniere et al. (42.1% and 36.4%, respectively) who concluded that outpatients with sarcopaenia were more likely to be frail than frail outpatients to be sarcopaenic [54]. Therefore, although sarcopaenia and frailty are related processes and indeed there is some overlap between the criteria that define them, the combined prevalence is low, which reflects the fact that they are different constructs and represent different types of pathophysiology. Sarcopaenia consists of impaired function and muscle mass, while frailty is a broader, multifactorial process that reduces homeostatic reserves. This slight degree of concordance corroborates the conclusions of previous research, in which the two diagnoses did not always coincide according to all definitions applied [54]. In addition, our results show that the intensity of the association between sarcopaenia and frailty was only weak-moderate (Cramer V = 0.45), a low intercorrelation previously reported by the Toledo Study of Healthy Aging (Cramer V = 0.16) [27]. Therefore, it is important to diagnose these conditions separately in order to perform the most appropriate intervention. In accordance with Thompson et al., we believe that individuals identified as frail would benefit from an assessment for sarcopaenia, and vice versa, as a joint assessment is more predictive of mortality than one of either condition alone [53].

It seems well established that progressive resistance training and an adequate protein intake help build muscle mass. In this respect, too, certain dietary interventions (mainly concerning amino acids, vitamin D, antioxidants, and other supplements) are currently...
being considered [55]. However, although sarcopenia is currently a topic of great interest, some authors have drawn attention to the possible adverse effects of overdiagnosis and of classifying this phenomenon as a disease. Indeed, it has not been shown that diagnosing sarcopenia reduces morbidity and mortality, or that the specific treatment for this condition produces better results than the general recommendations of appropriate physical exercise and diet. Moreover, the diagnostic criteria applied tend to be varied and even arbitrary [56]. In view of these considerations, we believe that while sarcopenia screening studies are positive, encouraging awareness of this condition, revealing its impact and underlining the necessity to adopt an appropriate lifestyle and diet, nevertheless unnecessary labelling should be avoided, and more and better evidence should be obtained about sarcopenia and its impact on the elderly population.

The study we describe has various strengths. It is based on the analysis of data obtained from a representative sample of healthcare centres and on the global assessment of the participants. The data considered are sufficient in quantity and quality, having been collected directly via personal interviews, anthropometric tests, and medical records. Moreover, in our opinion, the outpatient setting is ideal for assessing conditions such as frailty and sarcopenia because it is where large numbers of elderly patients are attended and where certain interventions are best performed. Among other strong points of our analysis, the EWGSOP diagnostic criteria were rigorously applied, and the cut-off points used to classify low muscle mass coincide with those of many other studies [40,41,44,57,58]. This parameter was assessed using BIA, as in most studies in the field, due to its accessibility, ease of use, and portability within the health centre. Although DXA is a more precise method, its use in clinical routine is limited by cost considerations and the need for more specialised equipment and personnel. In addition, data suggest there is a good correlation between BIA and DXA [59]. Among the limitations of the study are its cross-sectional design, which means that causal relationships cannot be established, and the fact that it was carried out in a single region and country, which reduces its external validity. However, we believe that the sample considered is representative of a large proportion of community-dwelling older adults, and that the findings found provide a good reflection of circumstances in similar socio-sanitary environments. Another possible limitation of the study is not having considered among the exclusion criteria possible cachexia status, such as cancer and COPD, which are circumstances that can also cause muscle loss.

5. Conclusions

According to the EWGSOP criteria, sarcopenia is a common condition among community-dwelling older persons and may be associated with factors such as age, body mass index, and the presence of one or more psychopathologies. The latter predictive factor may be modifiable or treatable, and thus constitutes a possible area of intervention. Therefore, more attention should be paid to certain signs (or symptoms) to better detect anxiety and depression in the elderly, as these processes tend to be underdiagnosed and appropriate remedial measures would promote healthy aging. Sarcopenia and frailty are related but separate conditions and require specific approaches.

Author Contributions: Conceptualization, E.B.-R. and G.A.-Z.; methodology, E.B.-R. and R.O.-R.; formal analysis, E.B.-R. and R.O.-R.; investigation, E.B.-R., R.O.-R., G.A.-Z., L.A.-C., M.R.G.-M., J.V., C.T.-B. and I.B.-E.; resources, E.B.-R. and I.B.-E.; data curation: L.A.-C., M.R.G.-M., J.V., and C.T.-B.; writing—original draft preparation, E.B.-R., R.O.-R. and G.A.-Z.; writing—review and editing, E.B.-R., R.O.-R., G.A.-Z. and I.B.-E.; visualization, E.B.-R., R.O.-R. and I.B.-E.; supervision, E.B.-R.; project administration, E.B.-R.; funding acquisition: E.B.-R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Fundación Pública Andaluza Progreso y Salud, Con-sejería de Salud, Junta de Andalucía, through the Programme Proyectos de Investigación Biomédica (Grant number PI 0234/14). The APC was funded by the University of Málaga. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Málaga Clinical Research Ethics Committee (protocol EBR-MED-2013-01, PI-0234-14; approval date, 25 July 2013).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data that support the findings of this study are not publicly available due to being used for further investigational objectives and because the data contain information that could compromise the privacy of research participants. However, specific information can be obtained from the corresponding author upon reasonable request (E.B.-R.).

**Acknowledgments:** The authors wish to thank the Primary Care Management Team (Health District of Málaga-Guadalhorce) for providing access to the health centres and patient lists.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Rosenberg, I.H. Summary comments: Epidemiological and methodological problems in determining nutritional status of older people. *Am. J. Clin. Nutr.* 1989, 50, 1221–1233. [CrossRef]

2. Rosenberg, I.H. Sarcopenia: Origins and clinical relevance. *J. Nutr.* 1997, 127, 9905–9915. [CrossRef] [PubMed]

3. Goodpaster, B.H.; Park, S.W.; Harris, T.B.; Kritchevsky, S.B.; Nevitt, M.; Schwartz, A.V.; Simonsick, E.M.; Tylavsky, F.A.; Visser, M.; Newman, A.B. The loss of skeletal muscle strength, mass, and quality in older adults: The health aging and body composition study. *J. Gerontol. A Biol. Sci. Med. Sci.* 2006, 61, 1059–1064. [CrossRef] [PubMed]

4. Janssen, I.; Baumgartner, R.; Ross, R.; Rosenberg, I.H.; Roubenoff, R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. *Am. J. Epidemiol.* 2004, 159, 413–421. [CrossRef]

5. Cruz-Jentoft, A.J.; Bayens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.-P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010, 39, 412–423. [CrossRef] [PubMed]

6. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyere, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Aging* 2019, 48, 16–31. [CrossRef]

7. Anker, S.D.; Morley, J.E.; von Haehling, S. Welcome to the ICD-10 code for sarcopenia. *J. Cachexia Sarcopenia Muscle* 2016, 7, 512–514. [CrossRef]

8. 2022 ICD-10-CM Diagnosis Code M62.84. Sarcopenia. Available online: https://www.icd10data.com/ICD10CM/Codes/M00-M99/M60-M63/M62- /M62.84 (accessed on 30 May 2022).

9. International Working Group on Sarcopenia. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. *J. Am. Med. Dir. Assoc.* 2011, 12, 249–256. [CrossRef]

10. Cruz-Jentoft, A.J.; Landi, F.; Schneider, S.M.; Zúñiga, C.; Arai, H.; Boirie, Y.; Chen, L.-K.; Fielding, R.A.; Martin, F.C.; Michel, J.-E.; et al. Prevalence of and interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age Aging* 2014, 43, 748–759. [CrossRef]

11. Lardies-Sánchez, B.; Sanz-Paris, A.; Boj-Carrceller, D.; Cruz-Jentoft, A.J. Systematic review: Prevalence of sarcopenia in ageing people using bioelectrical impedance analysis to assess muscle mass. *Eur. Geriatr. Med.* 2016, 7, 256–261. [CrossRef]

12. Shafiee, G.; Keshtkar, A.; Soltani, A.; Ahadi, Z.; Larijani, B.; Heshmat, R. Prevalence of sarcopenia in the world: A systematic review and meta-analysis of general population studies. *J. Diabetes Metab. Disord.* 2017, 16, 21. [CrossRef] [PubMed]

13. Mayhew, A.J.; Amog, K.; Phillips, S.; Parise, G.; McNicholas, P.D.; de Souza, R.J.; Thabane, L.; Raina, P. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: A systematic review and meta-analyses. *Ageing 2019*, 48, 48–56. [CrossRef] [PubMed]

14. Papadopoulou, S.K.; Tsitivatis, P.; Potsaki, P.; Papandreou, D. Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis. *J. Nutr. Health Aging* 2020, 24, 83–90. [CrossRef]

15. Mijnarends, D.M.; Luiking, Y.C.; Halfens, R.J.G.; Evers, S.M.A.A.; Lennaerts, E.L.A.; Verlaan, S.; Wallace, M.; Schols, J.M.G.A.; Meijers, J.M.M. Muscle, health and costs: A glance at their relationship. *J. Nutr. Health Aging* 2018, 22, 766–773. [CrossRef] [PubMed]

16. Bischoff-Ferrari, H.A.; Orav, J.E.; Kanis, J.A.; Rizzoli, R.; Schlögl, M.; Staehelin, H.B.; Willett, W.C.; Dawson-Hughes, B. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. *Osteoporos Int.* 2015, 26, 2793–2802. [CrossRef]

17. Schaap, L.A.; van Schoor, N.M.; Lips, P.; Visser, M. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: The longitudinal aging study Amsterdam. *J. Gerontol. A Biol. Sci. Med. Sci.* 2018, 73, 1199–1204. [CrossRef]

18. Malmstrom, T.K.; Miller, D.K.; Simonsick, E.M.; Ferrucci, L.; Morley, J.E. SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes. *J. Cachexia Sarcopenia Muscle* 2016, 7, 28–36. [CrossRef]
Morley, J.E.; Abbatecola, A.M.; Argiles, J.M.; Baracos, V.; Bauer, J.; Bhasin, S.; Cederholm, T.; Coats, A.J.S.; Cummings, S.R.; Evans, W.J.; et al. Sarcopenia with limited mobility: An international consensus. J. Am. Med. Dir. Assoc. 2011, 12, 403–409. [CrossRef]

Dos Santos, L.; Cyrino, E.S.; Antunes, M.; Santos, D.A.; Sardinha, L.B. Sarcopenia and physical independence in older adults: The independent and synergic role of muscle mass and muscle function. J. Cachexia Sarcopenia Muscle 2017, 8, 245–250. [CrossRef]

Beaudart, C.; Biver, E.; Regimster, J.Y.; Rizzoli, R.; Rolland, Y.; Bautmans, I.; Petermans, J.; Gillain, S.; Buckinx, F.; Dardevve, N.; et al. Validation of the SarQoL(R), a specific health-related quality of life questionnaire for Sarcopenia. J. Cachexia Sarcopenia Muscle 2017, 8, 238–244. [CrossRef]

De Buyser, S.L.; Petrovic, M.; Taes, Y.E.; Toye, K.R.C.; Kaufman, J.M.; Lapauw, B.; Goemaere, S. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing 2016, 45, 602–608. [CrossRef] [PubMed]

Liu, P.; Hao, Q.; Hai, S.; Wang, H.; Cao, L.; Dong, B. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: A systematic review and meta-analysis. Maturitas 2017, 103, 16–22. [CrossRef] [PubMed]

Montero-Errasquin, B.; Cruz-Jentoft, A.J. The value of sarcopenia in the prevention of disability. Med. Clin. 2019, 153, 243–244. [CrossRef] [PubMed]

Dent, E.; Morley, J.E.; Cruz-Jentoft, A.J.; Arai, H.; Kritchevsky, S.B.; Guralnik, J.; Bauer, J.M.; Pahor, M.; Clark, B.C.; Cesari, M.; et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening diagnosis and management. J. Nutr. Health Aging 2018, 22, 1148–1161. [CrossRef]

Foreman, K.J.; Marquez, N.; Dolgert, A.; Fukutuki, K.; Fullman, N.; McGaughey, M. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018, 392, 2052–2090. [CrossRef]

Davies, B.; García, F.; Ara, I.; Artalejo, F.R.; Rodríguez-Manás, L.; Walter, S. Relationship Between Sarcopenia and Frailty in the Toledo Study of Healthy Aging: A Population Based Cross-Sectional Study. J. Am. Med. Dir. Assoc. 2018, 19, 282–286. [CrossRef]

Yamada, M.; Nishiguchi, S.; Fukutani, N.; Tanigawa, T.; Yukutake, T.; Kayama, H.; Aoyama, T.; Arai, H. Prevalence of sarcopenia in community-dwelling Japanese older adults. J. Am. Med. Dir. Assoc. 2013, 14, 911–915. [CrossRef]

Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic. Dis. 1987, 40, 373–383. [CrossRef]

Pfeiffer, E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J. Am. Geriatr. Soc. 1975, 23, 433–441. [CrossRef] [PubMed]

Sheik, J.I.; Yesavage, J.A. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clin. Geront. 1986, 5, 165–173.

Lawton, M.P.; Brody, E.M. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9, 179–186. [CrossRef] [PubMed]

Kaiser, M.J.; Bauer, J.M.; Ramsch, C.; Uter, W.; Guigoz, Y.; Cederholm, T.; Sieber, C.C. MNA-International Group. Validation of the Mini Nutritional Assessment short-form (MNA-SF): A practical tool for identification of nutritional status. J. Nutr. Health Aging 2009, 13, 782–788. [CrossRef] [PubMed]

Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Grotti, D.; Seeman, T.; Tracy, R.; Kop, W.J.; Burke, G.; et al. Frailty in older adults: Evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 2001, 56, M146–M156. [CrossRef] [PubMed]

Janssen, I.; Heymsfield, S.B.; Baumgartner, R.N.; Ross, R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J. Appl. Physiol. 2000, 89, 465–471. [CrossRef] [PubMed]

Hosmer, D.W.; Lemeshow, S.; Sturdivant, R.X. Applied Logistic Regression, 3rd ed.; John Wiley & Sons: Hoboken, NJ, USA, 2013.

Petermann-Rocha, F.; Balartzi, V.; Lara, J.; Ho, F.K.; Pell, J.P.; Celis-Morales, C. Global prevalence of sarcopenia and severe sarcopenia: A systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2022, 13, 86–99. [CrossRef]

Fernandes, L.V.; Paiva, A.E.G.; Silva, A.C.B.; de Castro, I.C.; Santiago, A.F.D.; de Oliveira, E.P.; Porto, L.C. Prevalence of sarcopenia according to EWGSOP1 and EWGSOP2 in older adults and their associations with unfavorable health outcomes: A systematic review. Aging Clin. Exp. Res. 2022, 34, 505–514. [CrossRef]

Vángerová, T.; Michálková, H.; Dvořáčková, O.; Topinková, E. Comparison between EWGSOP1 and EWGSOP2 criteria and modelling of diagnostic algorithm for sarcopenic obesity in over 70 years old patients. Eur. Geriatr. Med. 2022, 13, 641–648. [CrossRef]

Volpato, S.; Bianchi, L.; Cherubini, A.; Landi, F.; Maggio, A.; Savino, E.; Bandinelli, S.; Ceda, G.P.; Guralnik, J.M.; Ferrucci, L. Prevalence and clinical correlates of sarcopenia in community-dwelling older people: Application of the EWGSOP definition and diagnostic algorithm. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69, 438–446. [CrossRef] [PubMed]

Smoliner, C.; Sieber, C.C.; Wirth, R. Prevalence of sarcopenia in geriatric hospitalized patients. J. Am. Med. Dir. Assoc. 2014, 15, 267–272. [CrossRef]

Kim, I. Age and gender differences in the relation of chronic diseases to activity of daily living (ADL) disability for elderly South Koreans: Based on representative data. J. Prev. Med. Public Health 2011, 4, 32–40. [CrossRef] [PubMed]

Barnabeu-Wittel, M.; González-Molina, A.; Fernández-Ojeda, R.; Diez-Manglano, J.; Salgado, F.; Soto-Martín, M.; Muniesa, M.; Ollero-Batruno, M.; Gómez-Salgado, J. Impact of Sarcopenia and Frailty in a Multicenter Cohort of Polypathological Patients. J. Clin. Med. 2019, 8, 535. [CrossRef] [PubMed]
44. Bianchi, L.; Abete, P.; Bellelli, G.; Bo, M.; Cherubini, A.; Corica, F.; Di, B.M.; Maggio, M.; Manca, G.M.; Rizzo, M.R.; et al. GLISTEN Group Investigators. Prevalence and Clinical Correlates of Sarcopenia, Identified According to the EWGSOP Definition and Diagnostic Algorithm, in Hospitalized Older People: The GLISTEN Study. *J. Gerontol. A Biol. Sci. Med. Sci.* 2017, 72, 1575–1581. [CrossRef]

45. Kirk, B.; Zanker, J.; Bani Hassan, E.; Bird, S.; Brennan-Olsen, S.; Duque, G. Sarcopenia Definitions and Outcomes Consortium (SDOC) Criteria are Strongly Associated With Malnutrition, Depression, Falls, and Fractures in High-Risk Older Persons. *J. Am. Med. Dir. Assoc.* 2021, 22, 741–745. [CrossRef] [PubMed]

46. Piliati, L; Slee, A.; Frost, R. Sarcopenic Obesity and Depression: A Systematic Review. *J. Frailty Aging* 2022, 11, 51–58. [CrossRef] [PubMed]

47. Fábrega-Cuadros, R.; Cruz-Díaz, D.; Martínez-Amat, A.; Aíbar-Almazán, A.; Redecillas-Peiró, M.T.; Hita-Contreras, F. Associations of sleep and depression with obesity and sarcopenia in middle-aged and older adults. *Maturitas* 2020, 142, 1–7.

48. Kume, Y.; Takahashi, T.; Itakura, Y.; Lee, S.; Makizako, H.; Ono, T. Polypharmacy and Lack of Joy Are Related to Physical Frailty among Northern Japanese Community-Dwellers from the ORANGE Cohort Study. *Gerontology* 2021, 67, 184–193. [CrossRef]

49. Blanco-Reina, E.; Aguilar-Cano, L.; García-Merino, M.R.; Ocaña-Riola, R.; Valdellós, J.; Bellido-Estévez, I.; Ariza-Zafra, G. Assessing Prevalence and Factors Related to Frailty in Community-Dwelling Older Adults: A Multinomial Logistic Analysis. *J. Clin. Med.* 2021, 10, 3576. [CrossRef]

50. Li, C.W.; Yu, K.; Shyh-Chang, N.; Jiang, Z.; Liu, T.; Ma, S.; Luo, L.; Guang, L.; Liang, K.; Ma, W.; et al. Pathogenesis of sarcopenia and the relationship with fat mass: Descriptive review. *J. Cachexia Sarcopenia Muscle* 2022, 13, 781–794. [CrossRef]

51. Marconcin, P.; Ihle, A.; Werneck, A.O.; Gouveia, E.R.; Ferrag, G.; Peralta, M.; Marques, A. The Association of Healthy Lifestyle Behaviors with Overweight and Obesity among Older Adults from 21 Countries. *Nutrients* 2021, 13, 315. [CrossRef]

52. Pérez-Rodrigo, C.; Gianzo Citores, M.; Hervás Bárbara, G.; Aranceta-Bartrina, J. Prevalence of obesity and abdominal obesity in Spanish population aged 65 years and over: ENPE study. *Med. Clin.* 2022, 58, 49–57. [CrossRef]

53. Thompson, M.Q.; Yu, S.; Tucker, G.R.; Adams, R.J.; Cesari, M.; Theou, O.; Visvanathan, R. Frailty and sarcopenia in combination are more predictive of mortality than either condition alone. *Maturitas* 2021, 144, 102–107. [CrossRef] [PubMed]

54. Reijnierse, E.M.; Trappenburg, M.C.; Blauw, G.J.; Verlaan, S.; de van der Schueren, M.A.; Meskers, C.G.; Maier, A.B. Common Ground? The Concordance of Sarcopenia and Frailty Definitions. *J. Am. Med. Dir. Assoc.* 2016, 17, e7–e12. [CrossRef] [PubMed]

55. Cruz-Jentoft, A.J.; Dawson Hughes, B.; Scott, D.; Sanders, K.M.; Rizzoli, R. Nutritional strategies for maintaining muscle mass and strength from middle age to later life: A narrative review. *Maturitas* 2020, 132, 57–64. [CrossRef] [PubMed]

56. Haase, C.B.; Brodersen, J.B.; Bülow, J. Sarcopenia: Early prevention or overdiagnosis? *BMJ* 2022, 376, e52592. [CrossRef]

57. Landi, F.; Liperoti, R.; Fusco, D.; Mastropalo, S.; Quattrociocchi, D.; Proia, A.; Tosato, M.; Bernabei, R.; Onder, G. Sarcopenia and mortality among older nursing home residents. *J. Am. Med. Dir. Assoc.* 2012, 13, 121–126. [CrossRef]

58. Legrand, D.; Vaes, B.; Mathei, C.; Swine, C.; Degryse, J.M. The prevalence of sarcopenia in very old individuals according to the European consensus definition: Insights from the BELFRAIL study. *Aging Ageing* 2013, 42, 727–734. [CrossRef]

59. Reiss, J.; Igl seder, B.; Kreutzer, M.; Weiß buchner, I.; Tresch nitzer, W.; Kassmann, H.; Pirich, C.; Reiter, R. Case finding for sarcopenia in geriatric inpatients: Performance of bioimpedance analysis in comparison to dual X-ray absorptiometry. *BMC Geriatr.* 2016, 16, 52. [CrossRef]